Sanofi Germany

What Sanofi Germany does

Sanofi Germany (legal entity: Sanofi-Aventis Deutschland GmbH) is the wholly-owned German operating subsidiary of French multinational biopharma group Sanofi S.A., headquartered at the Sanofi BioCampus within Industriepark Höchst in Frankfurt am Main. The company operates as a research-focused biopharma enterprise with 5,001–10,000 employees, developing, manufacturing, and commercializing innovative therapeutic solutions across multiple therapy areas including diabetes, respiratory diseases (COPD/asthma), oncology, immunology/rheumatology, vaccines, multiple sclerosis, rare diseases (e.g., Gaucher disease), and cardiovascular conditions. The Frankfurt facility has 100 years of continuous insulin manufacturing history, and over 60% of the research portfolio is biologics-based.

The company's technology stack combines proprietary drug-discovery platforms with AI-enabled research tools. Core proprietary platforms include NANOBODY® (single-domain antibody fragments derived from camelid heavy-chain antibodies enabling multispecific therapeutics), SYNTHORIN™ (synthetic biology for novel therapeutic candidates), and AAV-based viral vector systems for gene therapy delivery. R&D methods layer in digital tools — AI-driven in-silico/virtual patient models that simulate disease biology and drug response, digital toxicology predictive models, three-dimensional organoid cell structures from patient tissue, and machine learning pipelines that analyze gene expression, single-cell, and CRISPR screening datasets.

Sanofi Germany generates revenue from one-time sales of prescription medicines, vaccines, and diabetes care devices, distributed via GDP-certified pharmaceutical wholesalers to retail pharmacies and hospital pharmacies across the DACH region (Germany, Austria, Switzerland). The company runs an enterprise field-sales motion targeting healthcare professionals (with credential-gated access via DocCheck) and patients through dedicated digital channels including mein.sanofi.de, disease-specific websites (e.g., diabetes.sanofi.de, impfen.sanofi.de, mit-copd-leben.de), and the Health x Tomorrow digital innovation initiative. Pricing of prescription medicines is regulated under the German statutory health insurance framework, with proposed GKV-BStabG legislation threatening to raise the standard manufacturer discount from 7% to 15.5%.

Name

Sanofi Germany

Legal name

Sanofi-Aventis Deutschland GmbH

Website

https://sanofi.de

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Sanofi Germany (Sanofi-Aventis Deutschland GmbH) is the German subsidiary of Sanofi S.A., a research biopharma firm in Frankfurt that develops, manufactures, and sells prescription medicines, vaccines, biologics, and gene therapies across diabetes, respiratory, oncology, immunology, and rare diseases in the DACH region.

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Biologics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Prescription pharmaceuticals
• Biologics manufacturing
• Vaccine development
• Diabetes care solutions
• Rare disease treatments

Headquarters

HQ city

Frankfurt

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Pharmaceuticals: Revenue from prescription medicines across multiple therapy areas including diabetes, respiratory diseases, oncology, immunology, vaccines, and rare diseases. Products are distributed through pharmaceutical wholesale to pharmacies and hospital pharmacies.
2. Vaccines: Revenue from vaccine products for prevention of infectious diseases. Sanofi is a major global vaccines provider.
3. Diabetes Care Devices: Sanofi operates in the diabetes care devices market alongside competitors like Abbott, Dexcom, Medtronic, and Roche, offering diabetes management solutions.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Sanofi Germany is a research biopharma company that develops, manufactures, and distributes innovative prescription medicines, vaccines, and biologics across multiple therapy areas including diabetes, respiratory diseases (COPD/asthma), oncology, immunology, multiple sclerosis, rare diseases, and cardiovascular conditions. The company also offers medical devices such as auto-injectors and pre-filled syringes for self-administration, supported by proprietary technology platforms (NANOBODY, SYNTHORIN, AAV viral vectors) and AI-powered drug discovery tools including virtual patient models and organoid technology.

Product overview

Sanofi Germany is a research-focused biopharma company offering a broad portfolio of innovative medicines and digital health solutions. The portfolio spans multiple therapeutic areas including diabetes care, respiratory diseases (COPD/asthma), vaccines, oncology, immunology/rheumatology, multiple sclerosis, rare diseases, and cardiovascular conditions. Core products include biologics such as monoclonal antibodies and nanobodies, with supporting technology platforms like NANOBODY and SYNTHORIN for drug development. The company develops advanced genomic medicines using viral vectors and mRNA technology. Digital offerings include patient portals (mein.sanofi.de), disease-specific websites, and AI-powered research tools including virtual patient models and organoid technology for drug discovery.

Differentiator

Problem solved

Functional benefit

Brands

• Sanofi BioCampus: Biopharmaceutical research and manufacturing campus located in Frankfurt Höchst
• mein.sanofi.de
• Health x Tomorrow

Products and services

• Diabetes Care Portfolio Comprehensive diabetes management portfolio including insulin products, glucose monitoring support, and digital health tools for diabetes patients. Includes a century of insulin production expertise at the Frankfurt facility.
• Respiratory Disease Treatments Treatments for chronic obstructive pulmonary disease (COPD) and asthma, including biologic therapies for severe cases, addressing chronic respiratory symptoms and exacerbation prevention.
• Vaccines Portfolio Comprehensive vaccine portfolio for prevention of infectious diseases. Sanofi is a major global vaccines provider distributing through pharmaceutical wholesale channels.
• Oncology Treatments Cancer treatments including immunotherapies that harness the immune system to fight tumors, leveraging proprietary NANOBODY and biologics platforms for oncology applications.
• Multiple Sclerosis Treatments Treatments for multiple sclerosis patients, including modern therapies addressing disease progression and symptom control.
• Immunology and Rheumatology Treatments Biologics and advanced therapies for chronic inflammatory and autoimmune diseases including rheumatoid arthritis, leveraging biotechnology-manufactured antibody products.
• Rare Disease Treatments Specialized treatments for rare genetic and metabolic disorders including Gaucher disease and Hunter syndrome (lysosomal storage disorders).
• Auto-injectors and Application Aids Medical devices including self-injection auto-injectors, pre-filled syringes, and injection pens for precise self-administration of biologic medications at home.
• Genomic Medicine and Gene Therapies Gene therapies using viral vectors (AAV), mRNA technology, and non-viral delivery methods for treating inherited neurological and rare diseases.
• Cardiovascular Disease Treatments Treatments addressing LDL-cholesterol and other cardiovascular risk factors to reduce the risk of heart attack and stroke.

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature6 records

Partnerships

Four partnerships are on record, tiered operational.

• Workday Inc.operationalTechnology or IntegrationSanofi uses Workday's cloud-based human capital management platform for recruitment and applicant tracking. Job seekers are redirected to Workday for registration and application submission when applying for positions as 'Berufseinsteiger und -erfahrene' (entry-level and experienced professionals).
• DocCheck Medical Services GmbHoperationalTechnology or IntegrationDocCheck provides identity verification services for healthcare professional (HCP) authentication on Sanofi's password-protected professional portals. Healthcare professionals log in using their DocCheck credentials to verify their professional status before accessing prescription drug information.
• Provadis Partner für Bildung und Beratung GmbHoperationalChannel Partner/ Reseller/ DistributorSanofi partners with Provadis for managing applications from students and trainees (Werkstudenten und Auszubildende). Job seekers in these categories are redirected to Provadis's platform for application submission.
• Zoom Video CommunicationsoperationalTechnology or IntegrationSanofi uses Zoom for conducting online meetings, telephone conferences, webinars, and virtual events. Data processing occurs including in the USA with EU Standard Contractual Clauses and configuration for EU data centers.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Novo Nordisk: Direct rival in diabetes care (insulin and GLP-1), competing with Sanofi's diabetes franchise and benefitting from the same GLP-1 market tailwinds referenced in Sanofi's own materials.
• Boehringer Ingelheim: Headquartered in Germany and a major privately-held biopharma company with comparable respiratory, immunology, cardiometabolic, and biologics franchises, plus substantial German manufacturing footprint.
• Bayer (Pharmaceuticals): German-domiciled multinational pharmaceutical division with overlapping cardiovascular, women's health, and radiology pipelines, sharing the same SHI regulatory and pricing environment as Sanofi Germany.
• Merck KGaA: German-based life sciences company with pharmaceutical operations in oncology, neurology (MS — directly overlapping Sanofi's MS franchise), and immunology, plus comparable R&D infrastructure in Darmstadt.
• GSK: Global vaccines leader that competes head-to-head with Sanofi across pediatric and adult immunization portfolios and shares similar respiratory and specialty pharma franchises in the German market.
• Eli Lilly: Closely comparable competitor in diabetes/obesity (GLP-1), immunology, and oncology biologics, with overlapping European commercial footprint and pipeline ambitions.

Broad incumbents

• Roche: Global biopharma leader with strong oncology, immunology, and diagnostics portfolios — overlapping with Sanofi Germany on biologics, oncology, and rare disease franchises, and competing for the same hospital and specialty pharmacy channels in Germany.
• Novartis: Global Swiss pharma with directly overlapping immunology, oncology, and cardiovascular franchises, plus comparable investment in cell/gene therapy and biologics platforms competing with Sanofi's NANOBODY and SYNTHORIN platforms.
• Pfizer: Diversified global biopharma with overlapping vaccines, oncology, immunology, and rare disease portfolios, competing in the same hospital, retail pharmacy, and SHI reimbursement channels in Germany.
• AstraZeneca: Global biopharma with overlapping oncology, respiratory, and rare disease franchises and comparable investment in antibody engineering and biologics platforms that compete with Sanofi's proprietary technology stack.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/SanofiDE
• Xx.com/sanofiDE
• LinkedInlinkedin.com/company/sanofi-deutschland-gmbh

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanofi Germany